WuXi Biologics to Acquire Pfizer’s Biologics Manufacturing Facilities in China

 WuXi Biologics to Acquire Pfizer’s Biologics Manufacturing Facilities in China

WuXi Biologics to Acquire Pfizer’s Biologics Manufacturing Facilities in China

Shots:

  • WuXi Biologics signs an equity agreement with Pfizer to acquire its state-of-the-art biologics manufacturing facilities along with its labor force in Hangzhou, China. The transaction is expected to close in H1’21
  • The agreement will boost WuXi Biologics’ commercial DS & DP capabilities to address surging manufacturing demands
  • The state-of-the-art 50,000 m2 facilities include DS capacities equipped with 2x2000L single-use bioreactors expandable to 4x2000L (MFG20) and DP capacities of vial filling (DP9) and pre-filled syringe (DP10). Wuxi will commence the production following the deal closure

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: WuXi Biologics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post